Lord, Abbett & Co
IBRX icon

Lord, Abbett & Co’s ImmunityBio IBRX Stock Holding History

Lord, Abbett & Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-303,645
Closed -$3.48M – 918
2015
Q3 		$3.48M Buy
+303,645
New +$6.63M 0.01% 791

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Lord, Abbett & Co's IBRX Position: Q4 2015 in Review

Lord, Abbett & Co sold out of ImmunityBio (IBRX) in Q4 2015, closing a stake of 303,645 shares — an estimated $3.48M sold.

Lord, Abbett & Co first reported a position in IBRX in Q3 2015 and held it in 1 quarter. The position peaked at $3.48M in Q3 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2015.

  • Lord, Abbett & Co reported no remaining ImmunityBio position as of Q4 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 303,645 ImmunityBio shares in Q4 2015, an estimated $3.48M.
  • Lord, Abbett & Co first reported a position in ImmunityBio in Q3 2015 and held it in 1 quarter.
  • Lord, Abbett & Co's ImmunityBio position peaked at $3.48M in Q3 2015.
  • 61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2015.

Based on Lord, Abbett & Co's 13F filing for Q4 2015, filed 16 Feb 2016.